Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 7, Pages 1241-1248Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw150
Keywords
immunotherapy; vaccine; breast cancer; triple-negative breast cancer; HER2
Categories
Funding
- Antigen Express through Henry M. Jackson Foundation
- United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences
- Department of Clinical Investigation, Walter Reed Army Medical Center
- Jeanne F. Shelby Scholarship Fund
- National Institutes of Health [CA016672]
Ask authors/readers for more resources
This phase II trial of the AE37 vaccine shows no benefit in the intention-to-treat population. However, the trial confirms the vaccine to be safe and capable of stimulating an immune response. Prespecified subgroup analyses show the vaccine may reduce the recurrence rate in triple-negative breast cancer patients, suggesting an appropriate patient population for further clinical investigation.AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776-790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe and highly immunogenic. A prospective, randomized, multicenter phase II adjuvant trial was conducted to evaluate the vaccine's efficacy. Clinically disease-free node-positive and high-risk node-negative breast cancer patients with tumors expressing any degree of HER2 [immunohistochemistry (IHC) 1-3+] were enrolled. Patients were randomized to AE37 + GM-CSF versus GM-CSF alone. Toxicity was monitored. Clinical recurrences were documented and disease-free survival (DFS) analyzed. The trial enrolled 298 patients; 153 received AE37 + GM-CSF and 145 received GM-CSF alone. The groups were well matched for clinicopathologic characteristics. Toxicities have been minimal. At the time of the primary analysis, the recurrence rate in the vaccinated group was 12.4% versus 13.8% in the control group [relative risk reduction 12%, HR 0.885, 95% confidence interval (CI) 0.472-1.659, P = 0.70]. The Kaplan-Meier estimated 5-year DFS rate was 80.8% in vaccinated versus 79.5% in control patients. In planned subset analyses of patients with IHC 1+/2+ HER2-expressing tumors, 5-year DFS was 77.2% in vaccinated patients (n = 76) versus 65.7% in control patients (n = 78) (P = 0.21). In patients with triple-negative breast cancer (HER2 IHC 1+/2+ and hormone receptor negative) DFS was 77.7% in vaccinated patients (n = 25) versus 49.0% in control patients (n = 25) (P = 0.12). The overall intention-to-treat analysis demonstrates no benefit to vaccination. However, the results confirm that the vaccine is safe and suggest that vaccination may have clinical benefit in patients with low HER2-expressing tumors, specifically TNBC. Further evaluation in a randomized trial enrolling TNBC patients is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available